Berthiaume N, Claing A, Lippton H, Cadieux A, D'Orléans-Juste P
Department of Pharmacology, Medical School, Université de Sherbrooke, QC, Canada.
Can J Physiol Pharmacol. 1995 Jul;73(7):1080-3. doi: 10.1139/y95-154.
The present work was undertaken to study the effect of rat adrenomedullin (rADM (1-50) and its C-terminal fragment (11-50)) in the endothelium-intact arterial and venous vasculatures of the rat perfused mesenteric bed. rADM (1-50) and the fragment rADM (11-50)(1-1000 pmol) induced a dose-dependent and endothelium-independent vasodilation on the arterial mesenteric vasculature. However, both peptides were inactive on the venous side of this vascular bed. The CGRP1 receptor antagonist, hCGRP8-37 (1 microM), markedly reduced the vasodilation caused by rADM (1-50) in the arterial mesenteric vasculature. Thus, our results show that rADM (1-50) in the arterial mesenteric vasculature. Thus, our results show that rADM (1-50) and its C-terminal fragment rADM(11-50) share properties similar to those of hCGRP. The blocking effect of hCGRP8-37 supports a role for CGRP1 receptor activation by adrenomedullin in this vascular preparation.
本研究旨在探讨大鼠肾上腺髓质素（rADM (1-50)）及其C末端片段（11-50）对灌注肠系膜床的大鼠完整内皮动脉和静脉血管系统的影响。rADM (1-50)和片段rADM (11-50)（1-1000皮摩尔）对肠系膜动脉血管系统产生剂量依赖性且不依赖内皮的血管舒张作用。然而，这两种肽对该血管床的静脉侧均无活性。降钙素基因相关肽1（CGRP1）受体拮抗剂hCGRP8-37（1微摩尔）显著降低了rADM (1-50)在肠系膜动脉血管系统中引起的血管舒张作用。因此，我们的结果表明，rADM (1-50)在肠系膜动脉血管系统中……因此，我们的结果表明，rADM (1-50)及其C末端片段rADM(11-50)具有与hCGRP相似的特性。hCGRP8-37的阻断作用支持了肾上腺髓质素激活CGRP1受体在这种血管制剂中的作用。
